Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography.
Metabolic response monitoring early during chemotherapy may have a major impact on clinical management of patients with malignant lymphoma. In two patients with non-Hodgkin's lymphoma fluorine-18 fluorodeoxyglucose (18FDG) single-photon emission tomography (SPET) studies were performed during the first two chemotherapeutic cycles. Persisting uptake predicted treatment failure whereas a sharp reduction of 18FDG uptake was demonstrated in the case of a responsive tumour. Qualitative analysis of conventional 18FDG imaging may thus serve to identify patients with a non-responding tumour. The potential of this technique in the determination of the initial response remains to be established. Imaging with 18FDG and SPET appears promising as a more easily available methodology than 18FDG positron emission tomography.
Hoekstra
O S
OS
Department of Nuclear Medicine, Free University Hospital, Amsterdam, The Netherlands.
van Lingen
A
A
Ossenkoppele
G J
GJ
Golding
R
R
Teule
G J
GJ
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011241:Prednisone / Q000627:therapeutic use; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon; D014750:Vincristine / Q000627:therapeutic use
D019788:Fluorodeoxyglucose F18; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D003847:Deoxyglucose; D011241:Prednisone; D008727:Methotrexate